Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion
JAMA · 2023
DOI: 10.1001/jama.2023.4080 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA, 2023. Verfasst von Pierre Bouzat und 19 weiteren Autor:innen. Beteiligte Einrichtung: Université Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institute Neurosciences, Grenoble, France. Hauptthemen laut MEDLINE: Blood Coagulation Factors, Blood Transfusion, Factor IX, Hemorrhage. Die Arbeit wurde bisher 125-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Optimal transfusion strategies in traumatic hemorrhage are unknown. Reports suggest a beneficial effect of 4-factor prothrombin complex concentrate (4F-PCC) on blood product consumption.
Objective
To investigate the efficacy and safety of 4F-PCC administration in patients at risk of massive transfusion. Design, Setting, and Participants Double-blind, randomized, placebo-controlled superiority trial in 12 French designated level I trauma centers from December 29, 2017, to August 31, 2021, involving consecutive patients with trauma at risk of massive transfusion. Follow-up was completed on August 31, 2021.
Interventions
Intravenous administration of 1 mL/kg of 4F-PCC (25 IU of factor IX/kg) vs 1 mL/kg of saline solution (placebo). Patients, investigators, and data analysts were blinded to treatment assignment. All patients received early ratio-based transfusion (packed red blood cells:fresh frozen plasma ratio of 1:1 to 2:1) and were treated according to European traumatic hemorrhage guidelines. Main Outcomes and Measures The primary outcome was 24-hour all blood product consumption (efficacy); arterial or venous thromboembolic events were a secondary outcome (safety).
Results
Of 4313 patients with the highest trauma level activation, 350 were eligible for emergency inclusion, 327 were randomized, and 324 were analyzed (164 in the 4F-PCC group and 160 in the placebo group). The median (IQR) age of participants was 39 (27-56) years, Injury Severity Score was 36 (26-50 [major trauma]), and admission blood lactate level was 4.6 (2.8-7.4) mmol/L; prehospital arterial systolic blood pressure was less than 90 mm Hg in 179 of 324 patients (59%), 233 patients (73%) were men, and 226 (69%) required expedient hemorrhage control. There was no statistically or clinically significant between-group difference in median (IQR) total 24-hour blood product consumption (12 [5-19] U in the 4F-PCC group vs 11 [6-19] U in the placebo group; absolute difference, 0.2 U [95% CI, −2.99 to 3.33]; P = .72). In the 4F-PCC group, 56 patients (35%) presented with at least 1 thromboembolic event vs 37 patients (24%) in the placebo group (absolute difference, 11% [95% CI, 1%-21%]; relative risk, 1.48 [95% CI, 1.04-2.10]; P = .03). Conclusions and Relevance Among patients with trauma at risk of massive transfusion, there was no significant reduction of 24-hour blood product consumption after administration of 4F-PCC, but thromboembolic events were more common. These findings do not support systematic use of 4F-PCC in patients at risk of massive transfusion. Trial Registration ClinicalTrials.gov Identifier: NCT03218722
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institute Neurosciences, Grenoble, France.
- Trauma Critical Care Unit, Montpellier University Hospital, F-34295 Montpellier Cedex 5, France.
- Department of Anesthesiology and Critical Care, Beaujon Hospital, DMU Parabol, AP-HP. Nord, Clichy, France.
- Department of Anesthesiology and Critical Care, Centre Hospitalier Universitaire Lille, Surgical Critical Care, Lille, France.
- AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Département d'Anesthésie Réanimation, Paris, France.
- Aix Marseille University, Assistance Publique Hôpitaux Universitaires de Marseille, Department of Anesthesiology and Intensive Care Unit, North Hospital, and Centre for CardioVascular and Nutrition Research (C2VN), Inse…
Zitieren
APA
Bouzat, P., Charbit, J., Abback, P. S., Huet-Garrigue, D., Delhaye, N., Leone, M., Marcotte, G., David, J. S., Levrat, A., Asehnoune, K., Pottecher, J., Duranteau, J., Courvalin, E., Adolle, A., Sourd, D., Bosson, J. L., Riou, B., Gauss, T., Payen, J. F., & PROCOAG Study Group (2023). Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion. JAMA. https://doi.org/10.1001/jama.2023.4080
Vancouver
Bouzat P, Charbit J, Abback PS, Huet-Garrigue D, Delhaye N, Leone M, et al. Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion. JAMA. 2023. doi:10.1001/jama.2023.4080
BibTeX
@article{Bouzat2023,
author = {Bouzat, Pierre and Charbit, Jonathan and Abback, Paer-Selim and Huet-Garrigue, Delphine and Delhaye, Nathalie and Leone, Marc and Marcotte, Guillaume and David, Jean-Stéphane and Levrat, Albrice and Asehnoune, Karim and Pottecher, Julien and Duranteau, Jacques and Courvalin, Elie and Adolle, Anais and Sourd, Dimitri and Bosson, Jean-Luc and Riou, Bruno and Gauss, Tobias and Payen, Jean-François and PROCOAG Study Group, PROCOAG Study Group},
title = {Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.4080}
}
EUVIMED